Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Corn oil is a vegetable oil derived from the germ of corn (maize), primarily composed of polyunsaturated fatty acids such as linoleic acid. In the context of AstraZeneca's cardiovascular clinical research, corn oil was utilized as the placebo control in the large-scale Phase III STRENGTH trial. This trial was designed to evaluate the efficacy of Epanova (omega-3 carboxylic acids) in reducing major adverse cardiovascular events (MACE) in statin-treated patients with hypertriglyceridemia and high cardiovascular risk. Corn oil was selected as a comparator because it was considered a neutral lipid control that would not interfere with cardiovascular outcomes. The STRENGTH trial was terminated early in January 2020 after an interim analysis by an independent Data Monitoring Committee concluded that Epanova was unlikely to demonstrate a clinical benefit over the corn oil placebo.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on corn oil.